- Home
- ELVR vs DSGN Comparison
ELVR vs DSGN Comparison
Compare ELVR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVR
- DSGN
- Stock Information
- Founded
- ELVR N/A
- DSGN 2017
- Country
- ELVR Australia
- DSGN United States
- Employees
- ELVR N/A
- DSGN N/A
- Industry
- ELVR Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- ELVR Industrials
- DSGN Health Care
- Exchange
- ELVR Nasdaq
- DSGN Nasdaq
- Market Cap
- ELVR 254.1M
- DSGN 208.9M
- IPO Year
- ELVR N/A
- DSGN 2021
- Fundamental
- Price
- ELVR $24.93
- DSGN $6.54
- Analyst Decision
- ELVR
- DSGN
- Analyst Count
- ELVR 0
- DSGN 0
- Target Price
- ELVR N/A
- DSGN N/A
- AVG Volume (30 Days)
- ELVR N/A
- DSGN 173.8K
- Earning Date
- ELVR N/A
- DSGN 11-06-2025
- Dividend Yield
- ELVR N/A
- DSGN N/A
- EPS Growth
- ELVR N/A
- DSGN N/A
- EPS
- ELVR N/A
- DSGN N/A
- Revenue
- ELVR N/A
- DSGN N/A
- Revenue This Year
- ELVR N/A
- DSGN N/A
- Revenue Next Year
- ELVR N/A
- DSGN N/A
- P/E Ratio
- ELVR N/A
- DSGN N/A
- Revenue Growth
- ELVR N/A
- DSGN N/A
- 52 Week Low
- ELVR N/A
- DSGN $2.60
- 52 Week High
- ELVR N/A
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- ELVR N/A
- DSGN 54.51
- Support Level
- ELVR N/A
- DSGN $5.88
- Resistance Level
- ELVR N/A
- DSGN $7.59
- Average True Range (ATR)
- ELVR 0.00
- DSGN 0.51
- MACD
- ELVR 0.00
- DSGN -0.06
- Stochastic Oscillator
- ELVR 0.00
- DSGN 37.42
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.